CILP specifications

Information


Unique identifier OMICS_31236
Name CILP
Alternative name Correlation by Individual Level Product
Software type Package/Module
Interface Command line interface
Restrictions to use None
Operating system Unix/Linux, Mac OS, Windows
Programming languages R
Computer skills Advanced
Stability Stable
Maintained Yes

Download


download.png

Versioning


No version available

Maintainer


  • person_outline Amanda Lea

Publication for Correlation by Individual Level Product

CILP institution(s)
Department of Ecology and Evolution, Princeton University, Princeton, NJ, USA; Lewis Sigler Institute for integrative genomics, Princeton University, Princeton, NJ, USA; Department of Medicine, Lung Biology Center, San Francisco, CA, USA; Department of Human Genetics, David Geffen School of Medicine, Los Angeles, CA, USA; Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; Department of Clinical Physiology, Pirkanmaa Hospital District and and Finnish Cardiovascular Research CenterTampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; Systems Epidemiology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland; NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland; Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK; Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash University, Melbourne, VIC, Australia
CILP funding source(s)
Supported by National Institutes of Health (NIH) grants GM124881, HL-095056 and HL-28481; by a postdoctoral fellowship from the Helen Hay Whitney Foundation, by NIH grant F31HL127921; by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; and EU Horizon 2020 (grant 755320 for TAXINOMISIS).

CILP reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review CILP